不同降温技术用于目标温度管理的效果:一项前瞻性干预研究
该研究为前瞻性多中心研究,在UPMC医疗系统3家医院的10个ICU开展,连续筛查129例心脏骤停后接受低温治疗的患者,最终纳入120例,比较四种降温技术(共七种方法):两种外部水循环降温毯(Meditherm®与Blanketrol®)、凝胶黏附降温贴片(Arctic Sun®)、以及以冰盐水循环球囊的血管内降温导管(Thermogard®,含2、3、4个水循环球囊三种导管)。结果显示,降温速率以血管内降温最快(2.06±1.12 °C/h),Arctic Sun为1.49±0.82 °C/h,Meditherm为0.61±0.36 °C/h,Blanketrol为1.22±1.12 °C/h;维持期温度在目标±0.5 °C范围内的时间占比,Thermogard为97.3±6.0%,Arctic Sun为81.8±25.2%,Meditherm为57.4±29.3%,Blanketrol为64.5±20.1%。作者结论认为,血管内降温和凝胶黏附贴片在诱导速度及更重要的维持期达标时间上均优于水循环降温毯,且各设备均未发生重大并发症。
要点
- 降温速率:血管内降温2.06±1.12 °C/h、Arctic Sun 1.49±0.82 °C/h、Blanketrol 1.22±1.12 °C/h、Meditherm 0.61±0.36 °C/h。
- 维持期目标±0.5 °C内时间占比:Thermogard 97.3±6.0%、Arctic Sun 81.8±25.2%、Blanketrol 64.5±20.1%、Meditherm 57.4±29.3%。
- 温度达标时间占比的差异有统计学意义:Thermogard vs Meditherm(p<0.01)、Thermogard vs Blanketrol(p<0.01)、Arctic Sun vs Meditherm(p<0.02)。
- 作者认为维持期达标时间比单纯诱导速度更能反映设备性能,并据此评价四种降温系统。
- 所有设备均未发生重大并发症,各组基线特征相似。
适用人群与场景
- 心脏骤停后接受低温治疗(32-36 °C)的患者,研究纳入120例连续病例,来自3家医院10个ICU。
处置流程与药物剂量
- 低温治疗方案涵盖诱导、维持及随后控制性复温;研究由两名全职研究人员监测所有患者的治疗,包括抗寒战措施和额外降温措施(如冰袋和冷液体输注)。
研究设计与关键结果
- 前瞻性多中心研究,在UPMC医疗系统3家医院的10个ICU开展,筛查129例、纳入120例心脏骤停后低温治疗患者,比较两种外部水循环降温毯(Meditherm®与Blanketrol®)、凝胶黏附降温贴片(Arctic Sun®)及血管内降温导管(Thermogard®,含2、3、4个水循环球囊三种导管)共七种降温方法。
- 降温速率:血管内降温2.06±1.12 °C/h,Arctic Sun 1.49±0.82 °C/h,Meditherm 0.61±0.36 °C/h,Blanketrol 1.22±1.12 °C/h。
- 维持期温度在目标±0.5 °C内的时间占比:Thermogard 97.3±6.0%,Arctic Sun 81.8±25.2%,Meditherm 57.4±29.3%,Blanketrol 64.5±20.1%。
- 上述差异有统计学意义:Thermogard vs Meditherm(p<0.01)、Thermogard vs Blanketrol(p<0.01)、Arctic Sun vs Meditherm(p<0.02)。
- 各设备均未发生重大并发症,各组基线特征相似。
- 作者结论认为,与水温循环降温毯相比,血管内降温和凝胶黏附贴片能更快速诱导低温并更有效维持温度,这一优势同时体现在诱导速度和维持期达标时间上。
对床旁实践的改变
- 作者认为,选择降温设备时除诱导速度外,应重视维持期温度在目标±0.5 °C内的时间占比,血管内降温和凝胶黏附贴片在该指标上表现更优。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「证据类型、等级与局限」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Mild therapeutic hypothermia (32-36 °C) is associated with improved outcomes in patients with brain injury after cardiac arrest (CA). Various devices are available to induce and maintain hypothermia, but few studies have compared the performance of these devices. We performed a prospective study to compare four frequently used cooling systems in inducing and maintaining hypothermia followed by controlled rewarming.
METHODS: We performed a prospective multi-centered study in ten ICU's in three hospitals within the UPMC health system. Four different cooling technologies (seven cooling methods in total) were studied: two external water-circulating cooling blankets (Meditherm® and Blanketrol®), gel-coated adhesive cooling pads (Arctic Sun®), and endovascular cooling catheters with balloons circulating ice-cold saline (Thermogard®). For the latter system we studied three different types of catheter with two, three or four water-circulating balloons, respectively. In contrast to previous studies, we not only studied the cooling rate (i.e., time to target temperature) in the induction phase, but also the percentage of the time during the maintenance phase that temperature was on target ±0.5 °C, and the efficacy of devices to control rewarming. We believe that these are more important indicators of device performance than induction speed alone.
RESULTS: 129 consecutive patients admitted after CA and treated with hypothermia were screened, and 120 were enrolled in the study. Two researchers dedicated fulltime to this study monitored TH treatment in all patients, including antishivering measures, additional cooling measures used (e.g. icepacks and cold fluid infusion), and all other issues related to temperature management. Baseline characteristics were similar for all groups. Cooling rates were 2.06 ± 1.12 °C/h for endovascular cooling, 1.49 ± 0.82 for Arctic sun, 0.61 ± 0.36 for Meditherm and 1.22 ± 1.12 for Blanketrol. Time within target range ±0.5 °C was 97.3 ± 6.0% for Thermogard, 81.8 ± 25.2% for Arctic Sun, 57.4 ± 29.3% for Meditherm, and 64.5 ± 20.1% for Blanketrol. The following differences were significant: Thermogard vs. Meditherm (p < 0.01), Thermogard vs. Blanketrol (p < 0.01), and Arctic Sun vs. Meditherm (p < 0.02). No major complications occurred with any device.
CONCLUSIONS: Endovascular cooling and gel-adhesive pads provide more rapid hypothermia induction and more effective temperature maintenance compared to water-circulating cooling blankets. This applied to induction speed, but (more importantly) also to time within target range during maintenance.
参考来源
- Sonder P, Janssens GN, Beishuizen A, et al. Efficacy of different cooling technologies for therapeutic temperature management: A prospective intervention study. Resuscitation. 2017. PMID: 29288014. doi:10.1016/j.resuscitation.2017.12.026
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。